Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: An observational study in primary care

European Psychiatry

Volumn 23, Issue 3, 2008, Pages 178-186

  Begré, Stefan ^a   Traber, Martin ^b   Gerber, Martin ^c   von Känel, Roland ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Wyeth Pharmaceuticals AG   (Switzerland)

^c GEM Clinical Research Consulting M Gerber   (Switzerland)

Author keywords

Antidepressant; Clinical care; Pain; Primary care; Psychiatry in Europe; Switzerland; Unipolar depression; Venlafaxine

Indexed keywords

VENLAFAXINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; THORAX PAIN; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHRONIC DISEASE; COMORBIDITY; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PRIMARY HEALTH CARE; SOMATOFORM DISORDERS; SWITZERLAND; TREATMENT OUTCOME;

EID: 40849101524     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.01.001     Document Type: Article

References (47)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.; 1994.
2. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 7 5 (2000) 257-277
3. Arnow B.A., Hunkeler E.M., Blasey C.M., Lee J., Constantino M.J., Fireman B., et al. Comorbid depression, chronic pain, disability in primary care. Psychosom Med 68 2 (2006) 262-268
4. Bagby R.M., Ryder A.G., Schuller D.R., and Marshall M.B. The Hamilton depression rating scale: has the gold standard become a lead weight?. Am J Psychiatry 161 12 (2004) 2163-2177
5. Bair M.J., Robinson R.L., Katon W., and Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 163 20 (2003) 2433-2445
6. Bair M.J., Robinson R.L., Eckert G.J., Stang P.E., Croghan T.W., and Kroenke K. Impact of pain on depression treatment response in primary care. Psychosom Med 66 1 (2004) 17-22
7. Bandelow B., Baldwin D.S., Dolberg O.T., Andersen H.F., and Stein D.J. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder?. J Clin Psychiatry 67 9 (2006) 1428-1434
8. Bradley R.H., Barkin R.L., Jerome J., DeYoung K., and Dodge C.W. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 10 5 (2003) 318-323
9. Bryson H.M., and Wilde M.I. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 8 6 (1996) 459-476
10. Debonnel G., Saint-Andre E., Hebert C., de Montigny C., Lavoie N., and Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 10 1 (2007) 51-61
11. Dick I.E., Brochu R.M., Purohit Y., Kaczorowski G.J., Martin W.J., and Priest B.T. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 8 4 (2007) 315-324
12. Enggaard T.P., Klitgaard N.A., Gram L.F., Arendt-Nielsen L., and Sindrup S.H. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 69 4 (2001) 245-251
13. Fishbain D.A., Cutler R., Rosomoff H.L., and Rosomoff R.S. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 1 4 (2000) 310-316
14. Freeman E.W., Rickels K., Yonkers K.A., Kunz N.R., McPherson M., and Upton G.V. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 98 5 Pt 1 (2001) 737-744
15. Gureje O. Psychiatric aspects of pain. Curr Opin Psychiatry 20 1 (2007) 42-46
16. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clin Ther 25 8 (2003) 2138-2154
17. Guy W. ECDEU assessment manual for psychopharmacology. Revised ed. (1976), National Institute for Mental Health, Rockville
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 23 (1960) 56-62
19. Harvey A.T., Rudolph R.L., and Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57 5 (2000) 503-509
20. Janca A., and Hiller W. ICD-10 checklists - a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders. Compr Psychiatry 37 3 (1996) 180-187
21. Karp J.F. Venlafaxine XR and chronic pelvic pain syndrome. J Clin Psychiatry 65 6 (2004) 880-881
22. Khalifa M., Daleau P., and Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 291 1 (1999) 280-284
23. Kroenke K., Messina III N., Benattia I., Graepel J., and Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 67 1 (2006) 72-80
24. Max M.B. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol 35 Suppl. (1994) S50-S53
25. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., and Dubner R. Effects of desipramine, amitriptyline, fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 19 (1992) 1250-1256
26. Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 17 7 (2002) 335-339
27. Montauk S.L., and Martin J. Treating chronic pain. Am Fam Physician 55 4 (1997) 1151-1156
28. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349 9064 (1997) 1498-1504
29. Nierenberg A.A., Feighner J.P., Rudolph R., Cole J.O., and Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14 6 (1994) 419-423
30. Ozyalcin S.N., Talu G.K., Kiziltan E., Yucel B., Ertas M., and Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45 2 (2005) 144-152
31. Reuben S.S. The prevention of post-surgical neuralgia. Pain 113 1-2 (2005) 242-243
32. Rowbotham M.C., Goli V., Kunz N.R., and Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110 3 (2004) 697-706
33. Rudolph R.L., Fabre L.F., Feighner J.P., Rickels K., Entsuah R., and Derivan A.T. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59 3 (1998) 116-122
34. Saarto T., and Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 3 (2005) CD005454
35. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37 11 (2003) 1561-1565
36. Sindrup S.H., Otto M., Finnerup N.B., and Jensen T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96 6 (2005) 399-409
37. Sindrup S.H., Gram L.F., Skjold T., Froland A., and Beck-Nielsen H. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 47 4 (1990) 509-515
38. Sir A., D'Souza R.F., Uguz S., George T., Vahip S., Hopwood M., et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66 10 (2005) 1312-1320
39. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, tolerability in comparison with other classes of antidepressants. CNS Spectr 10 9 (2005) 732-747
40. Staiger T.O., Gaster B., Sullivan M.D., and Deyo R.A. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 28 22 (2003) 2540-2545
41. Songer D.A., and Schulte H. Venlafaxine for the treatment of chronic pain. Am J Psychiatry 153 5 (1996) 737
42. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59 10 (1998) 502-508
43. Thase M.E. Treatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 6 3 (2006) 269-282
44. Van Os T.W., Van den Brink R.H., Van der M.K., and Ormel J. The care provided by general practitioners for persistent depression. Eur Psychiatry 21 2 (2006) 87-92
45. Wang G.K., Russell C., and Wang S.Y. State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 110 1-2 (2004) 166-174
46. Wellington K., and Perry C.M. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 15 8 (2001) 643-669
47. Zissis N.P., Harmoussi S., Vlaikidis N., Mitsikostas D., Thomaidis T., Georgiadis G., et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 27 4 (2007) 315-324